Tag: Silo Pharma - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

Post published:May 13, 2021
Post category:Press Release

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Silo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics

Post published:April 28, 2021
Post category:Press Release

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Post published:April 22, 2021
Post category:Press Release

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology

Post published:April 7, 2021
Post category:Press Release

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into an Exclusive Option Agreement with the University of Maryland, Baltimore for patented Homing Peptides Targeting Rheumatoid Arthritis

Post published:March 4, 2021
Post category:Press Release

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Silo Pharma Licenses Novel Peptide-Guided Drug Delivery Approach for the Treatment of MS

Post published:February 18, 2021
Post category:Press Release

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Silo Pharma Announces Private Placement of Equity Definitive Agreement for $4.275 Million in Gross Proceeds

Post published:February 10, 2021
Post category:Press Release

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Post published:January 26, 2021
Post category:Press Release

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Silo Pharma Enters into Sponsored Research Agreement for Potential Multiple Sclerosis Treatment Approach with University of Maryland, Baltimore

Post published:January 13, 2021
Post category:Press Release

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Post published:January 11, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.